“Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma” has been added to your cart. View cart

Article: O.3 The anti-angiogenic peptide Anginex blocks osteoclastogenesis

€3.03

SKU: product-article-18975 Category: General

Description
Reviews (0)

Description

O.3 The anti-angiogenic peptide Anginex blocks osteoclastogenesis

Reviews

There are no reviews yet.

Be the first to review “Article: O.3 The anti-angiogenic peptide Anginex blocks osteoclastogenesis”

You must be logged in to post a review.

Top

Article: O.3 The anti-angiogenic peptide Anginex blocks osteoclastogenesis

Description

Reviews

Related products

Article: Highlights in breast cancer

Article: INTRODUCTION

Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer

Article: Highlights in breast cancer